Prostaglandin D 2 (PGD 2 ) binds to specific G-protein coupled receptors (DP) and induces smooth muscle relaxation by stimulating the synthesis of intracellular cAMP. In this study, we examined the role of PGD 2 and DP receptors in regulating human penile smooth muscle contractility. We determined that human corpus cavernosum tissue and smooth muscle cells in culture expressed functional DP receptor and lipocalin-like prostaglandin D synthase by reverse-transcribed polymerase chain reaction (RT-PCR). Functional PGD synthase activity was confirmed by the synthesis of PGD 2 in human corpus cavernosum smooth muscle cells upon addition of exogenous arachidonic acid. Organ bath preparations of human corpus cavernosum tissue strips, contracted with phenylephrine, relaxed in a dose-dependent fashion to either PGD 2 or the DP selective agonist BW245C. Cultures of human corpus cavernosum smooth muscle cells treated with BW245C showed a two-fold increase in cAMP synthesis. These data are consistent with the expression of functional DP receptors in human corpus cavernosum. This suggests the presence of an intact prostanoid autocrine system that may play a role in regulating penile erectile function.
Introduction
Prostanoids are bioactive lipids derived from 20-carbon, polyunsaturated fatty acids. The most common precursor is arachidonic acid. 1, 2 Prostaglandin G=H synthase (cox 1 and cox 2) converts arachidonic acid to prostaglandin H 2 , requiring oxygen as a co-substrate. Prostaglandin H 2 is then converted to PGD 2 , PGE 2 , PGF 2a , PGI 2 (prostacyclin) and TxA 2 (thromboxane A 2 ) by distinct synthases. These prostanoids interact with specific G-protein-coupled receptors and, depending on the prostanoid and receptor subtype, mediate smooth muscle relaxation or contraction. 1, 2 In the penis, the contractile state of corpus cavernosum smooth muscle is a major determinant of blood flow within the erectile tissue and regulates tumescence. 3, 4 In addition to their vasoactive properties, prostanoids play key roles in regulating diverse physiological processes. Prostaglandin D 2 modulates nociception, body temperature, olfactory function, sleep, immune response and hormone release in the central nervous system and in the periphery. 2,5 -7 The DP receptor, which binds PGD, is the least characterized with respect to expression and biochemical and physiological properties, relative to other prostanoid receptors. 2, 5 Detectable expression of human DP receptor mRNA has been reported only in the retina and small intestine. 2, 5 Cells transfected with the cloned human DP receptor cDNA or freshly isolated nonchromaffin cells from bovine adrenal medulla respond to prostaglandin D 2 and other DP agonists with increased cAMP synthesis and calcium mobilization. 5, 8 Prostaglandin D 2 is synthesized from PGH 2 by glutathione-independent, lipocalin PGD synthase or glutathione-dependent, hematopoietic PGD synthase; both of which have been cloned. 6, 9 The synthesis of PGE 2 , PGF 2a , PGI 2 and TxA 2 by human penile corpus cavernosum and the effects of these prostanoids on human corpus cavernosum tissue and smooth muscle cells have been previously reported. 3,10 -15 However, the synthesis of PGD 2 and the expression of functional DP receptors in human corpus cavernosum smooth muscle are yet to be determined. The goal of this study was to investigate the synthesis of PGD 2 in human corpus cavernosum and the ability of PGD 2 to elicit biological response in this tissue.
Materials and methods

Chemicals and supplies
BW245C, PGD 1 , PGD 2 and SQ29,548 were obtained from Cayman Chemical Company (Ann Arbor, MI). ELISA kits for PGD assay were obtained from R&D Systems (Minneapolis, MN) while cAMP radioimmunoassay kits were obtained from Biomedical Technologies (Stoughton, MA). Pfx Platinum polymerase, Taq DNA polymerase and Superscript II Moloney virus reverse transcriptase were obtained from Life Sciences (Rockville, MD). All other restriction endonucleases and molecular biological supplies were obtained from New England Biolabs (Beverly, MA), unless noted. All chemicals were of reagent grade.
RT-PCR assay for DP receptor expression
Primers for RT-PCR were designed such that they flanked one or more exon -intron junctions and were as follows: human DP receptor 5 0 -CAGAACCGGAG-TCTGCGG (nucleotides 614 -635), 3 0 -GGGACGCT-TCCCTCCCGTCC (nucleotides 1092 -1113) 5 and human lipocalin PGD synthase 5 0 -CACACCACTGG-CACCAGGCCC (nucleotides 40 -79), 3 0 -CCGGT AGCTGTAGGAGCCGAG (nucleotides 382 -430). 9 Total RNA from human kidney and small intestine was purchased from Clontech (Palo Alto, CA). Total RNA from human Jurkatt cells and from IMR90 human neonatal lung fibroblasts were the gifts from Drs Douglas Faller and Peter Polgar, respectively (Boston University School of Medicine, Boston, MA). Total RNA was prepared from human corpus cavernosum biopsies and cultured human corpus cavernosum smooth muscle cells as previously reported. 17 Reverse transcription was carried out as previously described 18 C, 72 C, 68 C for the DP receptor. Blunt-ended DNA fragments were isolated and cloned into pCR-Script AMP (Stratagene, La Jolla, CA) and DNA sequenced at our institutional core facility.
PGD 2 synthesis by human corpus cavernosum smooth muscle cells
Human corpus cavernosum smooth muscle cells were grown from tissue explants 17 and cultured on Cytodex TM III microcarrier beads (Pharmacia, Piscataway, NJ), as previously described for human corpus cavernosum smooth muscle cells 12 and human umbilical endothelial cells. 19 Cells were grown and maintained under low shear conditions at media PO 2 corresponding to blood PO 2 during penile erection (100 mm Hg). 20 Cells were incubated with exogenous 20 mM arachidonate for 30 min. Media was collected, treated with methyloxime to prevent decay of PGD 2 , clarified by centrifugation at 1000 g for 1 min, frozen in liquid nitrogen and stored at 770 C until assay. A commercially available ELISA kit (Cayman Chemicals, Ann Arbor, MI) was used to assess PGD 2 production. This protocol was repeated four times, using cells from four different patients.
Organ baths
The Institutional Review Boards at Boston University Medical Center and the Mayo Clinic and Foundation approved the use of human tissue. Human corpus cavernosum tissue was obtained during penile prosthesis insertion. Patients ranged from 45 to 70 y of age and had a variety of etiologies including radical prostatectomy, pelvic trauma, peripheral vascular disease, diabetes mellitus and Peyronie's disease. Organ bath experiments were carried out as previously reported. 15, 16 Human corpus cavernosum tissue strips at optimal isometric tension were contracted with 1 mM phenylephrine. After stable contraction was attained, tissue strips were exposed to increasing concentra- 
Measurement of cAMP synthesis
Human corpus cavernosum smooth muscle cells were prepared as previously reported. 17 Cells were grown to confluence in DMEM containing 25 U=ml penicillin, 250 U=ml streptomycin, 25 U=ml nystatin, and 2 mM glutamine and supplemented with 10% fetal bovine serum. The cells were re-fed with the same media 24 h before the experiment. Cells were incubated with 10 mM of 3-isobutyl-1-methylxanthine (IBMX) for 15 min and were then treated with increasing concentrations of BW245C (10 711 -10 76 M) for 5 min. The incubations were terminated by quickly aspirating the medium and adding ice-cold 1 N perchloric acid. Assays to quantify cAMP were performed, as previously described. 16 
Results
PGD synthesis in human corpus cavernosum
In order to determine if the lipocalin-like PGD synthase mRNA was expressed, RT-PCR was carried out utilizing total RNA from human corpus cavernosum biopsy specimens and cultured smooth muscle cells. Total RNA from human kidney, human small intestine, IMR90 cells and Jurkatt cells Figure 1A shows the amplification of a specific 370 bp band. The identity of this DNA product was established by digestion of the amplification products with the restriction endonuclease XhoI, which resulted in the expected 199 bp and 171 bp DNA fragments ( Figure 1B ). Subcloning and DNA sequencing of the amplification products further confirmed the identity of the product as lipocalin PGD synthase. The functional activity of PGD synthase in cultured human cavernosal smooth muscle cells was assessed by the measurement of PGD 2 in conditioned media. Under basal conditions, PGD 2 production was 0.23 AE 0.01 pmol=10 6 cells. When cells were exposed to 20 mM arachidonate in media with oxygen tension of 100 mm Hg (identical to blood PO 2 during penile erection), PGD 2 production increased to 4.03 AE 1.58 pmol=10 6 cells (n ¼ 4).
Expression of DP receptor mRNA in human corpus cavernosum
To determine if DP receptor mRNA was expressed in human corpus cavernosum, RT-PCR was carried out utilizing RNA from human corpus cavernosum whole tissue and cultured cavernosal smooth muscle cells. Total RNA from Jurkatt cells was used as a negative control, while human kidney, small intestine and IMR90 cells were used as positive controls. Figure 2A shows that RT-PCR of these samples resulted in a 484 bp amplified band in all the positive controls. The amplified band was detected in all four human corpus cavernosum biopsy specimens and in four of the five human cavernosal smooth muscle cell cultures, albeit to different degrees. The identity of this cDNA product was confirmed by restriction endonuclease digestion of the amplification products with ScaI, Figure 2 RT-PCR analysis of DP receptor expression in human tissues and cells. RT-PCR was carried out as described in the Methods section and products were separated on a non-denaturing 10% acrylamide gel. (A) Lane 1, DNA control; Lane 2, human kidney total RNA; Lane 3, human small intestines total RNA; Lane 4, human IMR90 cell total RNA; Lane 5, human Jurkatt cell total RNA; Lanes 6 -9, total RNA derived from human corpus cavernosum biopsies; Lanes 10 -13, total RNA derived from human corpus cavernosum smooth muscle cell cultures. (B) Identical samples digested with the restriction endonuclease ScaI.
Functional DP receptors in trabecular smooth muscle RB Moreland et al which resulted in the predicted 248 and 236 bp DNA fragments ( Figure 2B ). Subcloning and DNA sequencing of amplification products from both small intestine and human corpus cavernosum further confirmed the identity of the product as the DP receptor.
Effects of DP agonists in human corpus cavernosum
The structures of the DP agonists used in this study are shown in Figure 3 . In human corpus cavernosum tissue strips contracted with phenylephrine, both PGD 1 and the naturally occurring prostanoid PGD 2 caused smooth muscle relaxation to varying extents (Figure 4) . The estimated EC 50 for PGD 2 was $ 200 nM. At concentrations greater than 3 mM, PGD 2 induced contraction of corpus cavernosum muscle strips. Pre-incubation of muscle strips with 10 mM SQ29,548 inhibited this contraction, suggesting cross-reactivity with thromboxane A 2 receptors (data not shown). Of the three compounds tested, the DP-selective agonist BW245C was the most potent in relaxing human corpus cavernosum (EC 50 10 nM). The effects of BW245C were also examined in cultured smooth muscle cells isolated from human corpus cavernosum. In the presence of the nonselective, phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX), cAMP synthesis increased in a dose-dependent fashion, up to 2-fold over basal levels ( Figure 5 ).
Discussion
In this study, we have demonstrated the expression of the lipocalin PGD synthase, as well as functional activity evidenced by the synthesis of PGD 2 in human corpus cavernosum smooth muscle cell Functional DP receptors in trabecular smooth muscle RB Moreland et al cultures. Initially, it was proposed that the lipocalin PGD synthase was localized in the central nervous system and spinal fluid while the hematopoietic, glutathione-requiring PGD synthase was expressed in the peripheral tissues. 6 Recently, the presence of the hematopoietic PGD synthase, but not the lipocalin PGD synthase, was demonstrated by Northern blotting in the rat penis. 22 We were unable to detect the 23 kDa hematopoietic PGD synthase in human corpus cavernosum smooth muscle cell extracts by Western blotting, despite detection of the enzyme in other tissues (unpublished observations). It is interesting to note that expression of the lipocalin PGD synthase has been shown in human prostate, epididymis, and testis and PGD synthase activity was detected in seminal plasma. 23 However, this is the first report of lipocalin PGD synthase in the human corpus cavernosum penis. In addition to the synthesis of PGD 2 , we demonstrated the presence of DP receptors by RT-PCR of DP mRNA in both human corpus cavernosum whole tissue and cultured smooth muscle cells. Restriction enzyme analysis, cloning and sequencing of the amplified fragment from human corpus cavernosum and small intestine confirmed the identity of the DP receptor. We have also demonstrated functional DP receptors in human corpus cavernosum. Both the natural receptor ligand, PGD 2 and the DP receptor agonist BW245C caused relaxation of human cavernosal tissue strips. At the highest concentration of PGD 2 examined (10 mM), human corpus cavernosum tissue strips contracted, similar to what has been reported with dose responses to PGE 1 or misoprostol. 15 Since this contractile response could be prevented by the addition of the thromboxane A 2 antagonist SQ29,548, higher doses of PGD 2 probably cross-react with TP (thromboxane) receptors. A similar phenomenon has been reported in nonvascular smooth muscle in the lung, where PGD 2 plays a role in bronchoconstriction via TP receptors. 23 The pharmacological results are consistent with RT-PCR data demonstrating DP receptor mRNA in both corpus cavernosum smooth muscle biopsy specimens and cultured smooth muscle cells. The tissue distribution of the rat DP receptor has been characterized and found predominantly in the brain in the leptomeninges and peripherally in the eye and in the oviduct. Interestingly, no DP receptor mRNA was detected by Northern blot analysis of polyA RNA in the rat penis. 21 The estimated EC 50 values for PGD 2 and BW245C-induced relaxation in our study are comparable to those reported in embryonic bovine tracheal cells assayed for cAMP production (101 nM for PGD 2 and 59 nM for BW245C). 24 When cAMP production is assessed in transfected HEK293 cells expressing the human DP receptor, the effective doses of PGD 2 (EC 50 ¼ 6 nM) and BW245C (EC 50 ¼ 0.7 nM) are significantly lower. 5 This may be due to much greater numbers of receptors present on the HEK293 cells or a difference in signal transduction pathways inherent to the HEK cell line. In contrast, Chinese hamster ovary cells transfected with the recombinant mouse DP receptor, PGD 2 and BW245C competitively inhibited binding of radiolabeled PGD 2 with K i values of 21 nM and 250 nM, respectively. 23 This data is consistent with the differences observed for DP receptor binding of BW245C in mice versus humans. 2 We have previously demonstrated that PGE 1 causes cAMP levels to increase to 750 -1000 pmol=mg protein in human cavernosal smooth muscle cells through either the EP2 and=or EP4 receptors. 12, 16 This PGE 1 -induced increase in cAMP synthesis was observed to be proportional to the relaxation response. In contrast, the induction of cAMP synthesis by BW245C in the present study appears much less robust than the efficacy of DP agonists on smooth muscle relaxation. There was only a two-fold increase in cAMP synthesis (up to 23 pmol=mg protein) at 1 mM of BW245C, which caused relaxation in phenylephrine-contracted human cavernosal tissue strips. Since the major increase in intracellular cAMP occurs at much higher concentrations of BW245C, this may be due to crossover with the EP2 receptor as has been suggested in other systems. 26, 27 One of the mechanisms of smooth muscle relaxation in response to DP agonists may involve activation of calcium channels. A transient increase in intracellular calcium in response to DP agonists has been demonstrated in transfected as well as primary cell cultures. 5, 8 G as activation of L-type calcium channels has been shown with recombinant L-type calcium channels reconstituted into bilayers, 28 in cardiac myocytes via b-adrenergic receptor signaling as a down-regulation of receptor activity 29 and in transgenic mice overexpressing cardiac G as . 30 In the later report, activation of L-type calcium channels proceeded through a cAMP-independent pathway. 30 Thus, while cAMP may play a role in DP receptor signaling in human corpus cavernosum smooth muscle, the exact signal transduction pathways involved in smooth muscle relaxation remain to be determined.
Despite the reported discreet and limited expression of DP receptor mRNA in human tissues, 5 the presence of mRNA for DP receptor and PGD synthase and functional responses to DP agonists in human corpus cavernosum suggests a regulatory role for PGD 2 in erectile physiology. Penile erection is a complex hemodynamic physiological process involving central nervous system, peripheral nervous system and vascular regulatory components. Perhaps most interesting with regard to erectile function is the elegant work of Hayaishi and colleagues who have established a role for PGD 2 in the induction of both slow wave (SWS) and rapid eye movement (REM) sleep. 7, 31, 32 During REM sleep, most human males have three to five episodes of nocturnal penile tumescence. These erections have Functional DP receptors in trabecular smooth muscle RB Moreland et al been proposed to be key in the preservation of potency. 33 Thus, PGD 2 may influence erectile function through both local and central mechanisms. Further research is needed to understand the role of DP receptors and PGD synthase in the penis.
